Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

mber 31, 2012 was $46.2 million, or $0.66 and $0.62 income per basic and diluted earnings per share, respectively, compared to non-GAAP net income of $58.6 million, or $0.85 and $0.82 income per basic and diluted earnings per share, respectively for the quarter ended December 31, 2011.

Revenue for the six months ended December 31, 2012 was $160.7 million compared to $77.9 million for the six months ended December 31, 2011. Revenue for the quarter ended December 31, 2012 was $58.0 million compared to $77.9 million for the quarter ended December 31, 2011. Revenue for the quarter ended December 31, 2012 consisted primarily of $50.0 million of milestone revenue due to the Company's achievement of one clinical milestone in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") and $5.0 million of license revenue related to the Company's license agreement with Novo Nordisk A/S under which Novo Nordisk A/S acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology.

To date, the Company has received three milestone payments from Janssen of $50 million each, totaling $150 million, under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. Under the Agreeme
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... According to a new market ... Gel Electrophoresis, Agarose & Polyacrylamide Gel, Capillary Electrophoresis, Isoelectric ... & by End User - Global Forecast to 2020", ... reach around $1.98 Billion by 2020 with a CAGR ... Browse 226 ma rket data ...
(Date:5/22/2015)... Knowledgent , the data and analytics firm, ... of big data analytics in the life sciences and ... life sciences and healthcare organizations understand the ways in ... insights. , The life sciences and healthcare industries historically ... profiling, compliance and regulatory requirements, and scientific research. These ...
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Specialty ... audit and been admitted to BPA Worldwide as ... Worldwide will track audience data for Specialty Pharmacy ... , “By becoming a member of BPA ... to providing our clients with the most reliable, ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2
... 22 The International Executive Search Federation (IESF) is pleased ... network. IESF is the world,s largest retained executive search federation ... one of its global partners. The extensive network of over ... will considerably enhance IESF,s presence in the USA. The expanded ...
... Denmark, September 22 Bavarian,Nordic A/S (OMX: BAVA) yesterday ... (ECCO), ECCO 15 - 34th ESMO Congress in,Berlin, Germany. ... Phase II double-blind, prospective randomized,placebo-controlled study of 125 patients ... Senior Medical Director, BN,ImmunoTherapeutics. , ...
... Md., Sept. 22 Micromet, Inc. (Nasdaq: MITI ... treatment of cancer, inflammation and autoimmune diseases, today announced the ... and Chief Medical Officer effective November 1, 2009. ... clinical oncologist and has more than 20 years of experience ...
Cached Biology Technology:Sanford Rose Associates Joins the International Executive Search Federation 2New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 2New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 2Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 4
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... complicated at the best of times, but plants have an extra ... your flowers and reproduce, you will want your flowerstalks to be ... the crowd. But if your stalk is too long, you,ll stand ... lunch. It used to be thought that carnivorous plants like Sundews ...
... people,s health, but a new study suggests that having that ... stress. Unmarried people in a committed, romantic relationship show ... said Dario Maestripieri, Professor in Comparative Human Development at the ... in the current issue of the journal Stress . ...
... at the University of Gothenburg have shown how climate ... range of plants by modelling climate preferences for extinct ... what effects climate change of today and tomorrow will ... The researcher Mats Tpel at the Department of Plant ...
Cached Biology News:Sundews just want to be loved 2Marriage and committed romance reduce stress-related hormone production 2Climate change affects geographical range of plants 2
Polyclonal Antibody to AHI1 / Jouberin...
Request Info...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Polyclonal Antibody to PRG3...
Biology Products: